Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,520 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06028737RecruitingPhase 2/Phase 3
Chemotherapy before surgery for advanced stomach cancer
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
VilniusAges 18–80 - NCT07510308RecruitingPhase 1
Vaccine trial for advanced colorectal cancer
This trial tests a personalized vaccine made from your own tumor cells for advanced colorectal cancer that is mismatch repair proficient (pMMR). It aims to see if the vaccine can help when standard treatments have stopped working.
Chengdu, SichuanAges 18–75 - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Gilbert, ArizonaAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Birmingham, AlabamaAges 18 years+ - NCT06666270RecruitingPhase 1
SYN818 for advanced solid tumors with DNA repair defects
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Zhengzhou, HenanAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Goodyear, ArizonaAges 18 years+ - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT05406999RecruitingPhase 2
Intense hormone treatment before prostate surgery for high-risk cancer
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Nanjing, JiangsuAges 18–80 - NCT05378087Recruiting
Compare two ways to plan treatment for cervical cancer
This study compares two staging methods—using surgery results versus imaging tests—to help doctors plan treatment for locally advanced cervical cancer. It may improve how accurately the cancer is mapped, which could affect treatment choices and outcomes.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05687851RecruitingPhase 2
Cadonilimab plus radiation for locally advanced cervical cancer
This trial studies whether adding cadonilimab (an immune therapy) to standard radiation can improve treatment for locally advanced cervical cancer. It may help your immune system work better against the cancer while radiation shrinks it.
Chongqing, CHNAges 18 years+ - NCT07686640RecruitingPhase 3
Short course radiation plus chemo with or without immunotherapy for rectal cancer
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
Jinan, ShandongAges 18–75 - NCT07607119Recruiting
PULSAR radiation plus immunotherapy for advanced gastric cancer
This trial tests combining PULSAR (a type of radiation therapy) with immunotherapy drugs to treat gastric (stomach) cancer that cannot be surgically removed. You must have already completed at least 3 months of chemotherapy with immunotherapy and shown no cancer growth to qualify.
Seoul, Select Province/StateAges 19 years+ - NCT07469306RecruitingPhase 2
Comparing two radiation plans with chemo and immunotherapy for rectal cancer
This study compares two ways of giving radiation therapy for advanced rectal cancer, combined with a chemotherapy pill and an immunotherapy drug. One approach uses a shorter course of radiation before surgery, and the other uses a longer course; researchers want to see which is more effective and safer.
Fuzhou, FujianAges 18–75 - NCT07371611RecruitingPhase 3
Sintilimab plus chemo before and after surgery for advanced oral cancer
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
Guangzhou, GuangdongAges 18–75 - NCT07280832RecruitingPhase 1/Phase 2
JMT108 for advanced melanoma and urinary tract cancer
This study tests a new drug called JMT108 for advanced melanoma or urinary tract cancer. It may help your immune system attack the cancer, and the study is checking if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07286253RecruitingPhase 2
QL1706 plus chemo before surgery for advanced cervical cancer
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
Guangzhou, GuangdongAges 18–70 - NCT07269249Recruiting
Dostarlimab before surgery for advanced rectal cancer
This study looks at how well the immunotherapy drug dostarlimab works before surgery in patients with a specific type of advanced rectal cancer that has DNA repair problems (called dMMR/MSI-H). The goal is to see if it is safe and effective in the real world.
NaplesAges 18 years+ - NCT05646511RecruitingPhase 3
New chemotherapy timing tests for locally advanced rectal cancer
This Phase 3 trial compares two chemotherapy combinations given with surgery for locally advanced rectal cancer. It aims to find out which approach works better and is safer for shrinking and controlling the cancer before or around the time of treatment.
ChibaAges 18 years+ - NCT06944587Recruiting
Personalized care for advanced pancreatic cancer
This trial is testing a new way to treat pancreatic cancer that has spread to nearby tissues but not to distant organs. It uses a tailored plan that may include chemotherapy and possibly surgery. The goal is to see if this personalized approach helps people live longer and better.
Bergen, NorwayAges 18 years+ - NCT07104149RecruitingPhase 2
Chemo plus immunotherapy before surgery for cervical cancer
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
Zhengzhou, HenanAges 18–75
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,520 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.